Skip to main content

Table 1 The baseline characteristics of patients before and after PSM

From: Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma

  Before PSM After PSM
Characteristics TACE-Iodine 125 group TACE-RFA group P value TACE-Iodine 125 group TACE-RFA group P value
Age (Years) 58.2 ± 9.7 57.7 ± 8.9 0.787 58.1 ± 10 57.6 ± 8.2 0.824
ALT (U/L) 39.9 ± 20.6 48.8 ± 40.9 0.211 39.7 ± 20.9 45.9 ± 27.6 0.287
Hemoglobin (g/L) 122.2 ± 22.1 127 ± 22.4 0.284 122.2 ± 23 127.4 ± 24 0.361
Platelet (×109/L) 116 ± 58.5 131.1 ± 68.5 0.250 119 ± 59.7 138.7 ± 72.4 0.218
Lymphocyte(×109/L) 1.2 ± 0.6 1.3 ± 0.6 0.786 1.2 ± 0.6 1.2 ± 0.6 0.911
Neutrophil (×109/L) 3.2 ± 2.6 3.1 ± 1.7 0.712 3.3 ± 2.6 3.2 ± 1.9 0.939
Leukocyte (×109/L) 5.2 ± 3.1 5 ± 2.3 0.763 5.2 ± 3.2 5.2 ± 2.5 0.937
Gender (male, %) 78.9 87.8 0.214 80 88.6 0.324
HBV(+, %) 63.2 75.7 0.165 65.7 68.6 0.799
AFP (>200μg/L, %) 21.1 23 0.817 22.9 34.3 0.290
TACE number (≥2, %) 89.5 73 0.044 88.6 82.9 0.495
Tumor number (≥2, %) 65.8 35.1 0.002 62.9 60 0.806
Tumor size (> 3 cm, %) 65.8 56.8 0.356 34.3 20 0.179
CHILD (B, %) 34.2 23 0.204 37.1 28.6 0.445
BCLC (B, %) 68.4 41.9 0.008 65.7 82.9 0.101
  1. Abbreviations: HBV Hepatitis B Virus; + Positive, −, Other, ALT Alanine Aminotransferase; AST Aspartate Aminotransferase; AFP Alpha Fetoprotein; BCLC Barcelona Clinic Liver Cancer